Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise?
Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline…
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow…
Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study
Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in now. Novartis AG (NYSE:NVS) announced on…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Novartis Pharma AG Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of…
Roche’s prasinezumab shows promise on PD progression with five-year data
At the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Roche showcased new…
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk…
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk…
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and…
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk…